RXRX
Income statement / Annual
Last year (2024), Recursion Pharmaceuticals, Inc.'s total revenue was $58.84 M,
an increase of 32.00% from the previous year.
In 2024, Recursion Pharmaceuticals, Inc.'s net income was -$463.66 M.
See Recursion Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$58.84 M |
$44.58 M |
$39.68 M |
$10.00 M |
$3.41 M |
$1.71 M |
| Cost of Revenue |
$45.24 M
|
$42.59 M
|
$48.28 M
|
$9.10 M
|
$63.32 M
|
$45.81 M
|
| Gross Profit |
$13.60 M
|
$1.99 M
|
-$8.59 M
|
$896,000.00
|
-$59.91 M
|
-$44.10 M
|
| Gross Profit Ratio |
0.23
|
0.04
|
-0.22
|
0.09
|
-17.55
|
-25.77
|
| Research and Development Expenses |
$314.42 M
|
$241.23 M
|
$155.70 M
|
$135.27 M
|
$63.32 M
|
$45.81 M
|
| General & Administrative Expenses |
$178.18 M
|
$110.82 M
|
$81.60 M
|
$57.68 M
|
$25.26 M
|
$18.95 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$178.18 M
|
$110.82 M
|
$81.60 M
|
$57.68 M
|
$25.26 M
|
$18.95 M
|
| Other Expenses |
$0.00
|
-$699,000.00
|
-$162,000.00
|
-$178,000.00
|
-$549,000.00
|
-$608,000.00
|
| Operating Expenses |
$492.61 M
|
$351.35 M
|
$237.13 M
|
$192.78 M
|
$88.03 M
|
$64.15 M
|
| Cost And Expenses |
$537.84 M
|
$394.64 M
|
$285.41 M
|
$192.78 M
|
$88.03 M
|
$64.15 M
|
| Interest Income |
$15.76 M
|
$19.12 M
|
$6.25 M
|
$73,000.00
|
$336,000.00
|
$1.74 M
|
| Interest Expense |
$1.57 M
|
$97,000.00
|
$55,000.00
|
$2.95 M
|
$1.36 M
|
$635,000.00
|
| Depreciation & Amortization |
$36.49 M
|
$24.40 M
|
$19.49 M
|
$9.10 M
|
$4.44 M
|
$3.54 M
|
| EBITDA |
-$426.72 M |
-$299.57 M |
-$227.67 M |
-$174.42 M |
-$81.70 M |
-$58.34 M |
| EBITDA Ratio |
-7.25
|
-6.72
|
-5.74
|
-17.44
|
-23.94
|
-34.09
|
| Operating Income Ratio |
-8.14
|
-7.85
|
-6.19
|
-18.28
|
-24.79
|
-36.49
|
| Total Other Income/Expenses Net |
$14.22 M
|
$17.93 M
|
$6.25 M
|
-$3.70 M
|
-$2.39 M
|
$562,000.00
|
| Income Before Tax |
-$464.79 M
|
-$332.13 M
|
-$239.48 M
|
-$186.48 M
|
-$87.01 M
|
-$61.88 M
|
| Income Before Tax Ratio |
-7.9
|
-7.45
|
-6.04
|
-18.65
|
-25.49
|
-36.17
|
| Income Tax Expense |
-$1.13 M
|
-$4.06 M
|
-$55,000.00
|
-$8.41 M
|
$876,000.00
|
$646,000.00
|
| Net Income |
-$463.66 M
|
-$328.07 M
|
-$239.42 M
|
-$178.07 M
|
-$87.88 M
|
-$62.53 M
|
| Net Income Ratio |
-7.88
|
-7.36
|
-6.03
|
-17.81
|
-25.75
|
-36.54
|
| EPS |
-1.69 |
-1.58 |
-1.36 |
-1.05 |
-0.5248 |
-0.3732 |
| EPS Diluted |
-1.69 |
-1.58 |
-1.36 |
-1.05 |
-0.5248 |
-0.3732 |
| Weighted Average Shares Out |
$274.21 M
|
$207.85 M
|
$175.54 M
|
$170.27 M
|
$165.79 M
|
$165.79 M
|
| Weighted Average Shares Out Diluted |
$274.21 M
|
$207.85 M
|
$175.54 M
|
$170.27 M
|
$165.79 M
|
$165.79 M
|
| Link |
|
|
|
|
|
|
